

## Sprint Bioscience presents preclinical data from the DISA program at research conference

**Sprint Bioscience AB (publ) today announces that previously unpublished results from the company's DISA program will be presented at the conference STING & TLR-Targeting Therapies Summit in Boston, USA, May 9 - 11, 2023.**

The results show that the TREX1 inhibitors developed by Sprint Bioscience within the DISA program led to the activation of immune signaling in cancer cells from different types of tumors and that they have an effect that surpasses other inhibitors that are under development by other companies. The results have increased the understanding of how the TREX1 protein acts in cancer cells and how it enables these cells to escape the immune system.

"The results increase the mechanistic understanding and provide further support that inhibition of TREX1 has the opportunity to develop into a treatment option for patients with various types of cancer. We are proud to be able to present these data to the foremost researchers in the field," says Martin Andersson, CSO at Sprint Bioscience.

STING & TLR-Targeting Therapies Summit is a specialized conference with participants from companies and academic groups that focus on research and drug development with the aim of blocking the ability of cancer cells to escape the immune response in the tumor. The conference covers everything from basic research to clinical trials and many present previously completely unpublished information.

The poster 'Fragment-based drug development of TREX1 inhibitors' is presented by Yasmin Yu, Ph.D., Senior Scientist, Sprint Bioscience.

### **For further information, kindly contact:**

Martin Andersson, CSO, Sprint Bioscience  
Tel: 08-411 44 55  
Epost: [martin.andersson@sprintbioscience.com](mailto:martin.andersson@sprintbioscience.com)

### **About Sprint Bioscience AB (publ)**

Sprint Bioscience develops small-molecule *first-in-class* drug programs with a focus on oncology. Using fragment-based drug discovery, the company develops drug programs in a time- and resource-efficient way and then license them to global pharma companies during the preclinical phase. The company has successfully entered into several license agreements amounting to a potential value of USD 507 million in milestone payments as well as income from royalties on sales. The company is headquartered in Stockholm with laboratories in Huddinge. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and is traded under the short name SPRINT. Further information is available on the company's website; [www.sprintbioscience.com](http://www.sprintbioscience.com).

Certified Advisor is FNCA Sweden AB; [www.fnca.se](http://www.fnca.se).

Press Release  
02 May 2023 10:00:00 CEST



---

## Attachments

---

[Sprint Bioscience presents preclinical data from the DISA program at research conference](#)